Mature DCs can migrate into the tumor drain lymph node (TDLN) to prime and activate tumor‐specific T cells.[29] By examining TEM and TCM populations among CD8+ T cells in TDLNs, we found that the TCM and TEM proportions among CD8+ T cells in the PmTriTNE@CDA groups were highest of all the tested groups (Figure 5L,M), indicating that PmTriTNE@CDA could better coordinate adaptive and innate immune responses to fight cancer than the combination treatment groups. The gene discussed is CD8A; the disease is cancer.